ICON Public Limited Company (ICLR)
USD 144.02
(0.97%)
USD 144.02
(0.97%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.56 Billion USD | -20.83% |
| 2022 | 4.49 Billion USD | -7.15% |
| 2021 | 4.84 Billion USD | 1290.97% |
| 2020 | -406.69 Million USD | -518.49% |
| 2019 | -65.75 Million USD | -41.15% |
| 2018 | -46.58 Million USD | -170.56% |
| 2017 | 66.02 Million USD | -57.67% |
| 2016 | 155.97 Million USD | -36.62% |
| 2015 | 246.08 Million USD | 306.97% |
| 2014 | -118.9 Million USD | 34.86% |
| 2013 | -182.51 Million USD | -60.04% |
| 2012 | -114.04 Million USD | 4.35% |
| 2011 | -119.23 Million USD | 53.33% |
| 2010 | -255.5 Million USD | -76.82% |
| 2009 | -144.5 Million USD | -402.32% |
| 2008 | 47.79 Million USD | 165.59% |
| 2007 | 17.99 Million USD | 131.1% |
| 2006 | -57.87 Million USD | -6.19% |
| 2005 | -54.5 Million USD | 1.76% |
| 2004 | -55.47 Million USD | -396.0% |
| 2003 | -11.18 Million USD | 54.43% |
| 2002 | -24.54 Million USD | -7340.71% |
| 2001 | 339 Thousand USD | 101.43% |
| 2000 | -23.78 Million USD | -183.1% |
| 1999 | -8.4 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 3.24 Billion USD | -8.74% |
| 2024 Q3 | 2.73 Billion USD | -6.32% |
| 2024 Q2 | 3.07 Billion USD | -5.3% |
| 2023 Q2 | 4.17 Billion USD | -3.94% |
| 2023 FY | 3.56 Billion USD | -20.83% |
| 2023 Q1 | 4.34 Billion USD | -3.45% |
| 2023 Q4 | 3.56 Billion USD | -7.53% |
| 2023 Q3 | 3.85 Billion USD | -7.7% |
| 2022 Q3 | 4.36 Billion USD | -4.6% |
| 2022 FY | 4.49 Billion USD | -7.15% |
| 2022 Q1 | 4.73 Billion USD | -2.19% |
| 2022 Q2 | 4.57 Billion USD | -3.36% |
| 2022 Q4 | 4.49 Billion USD | 2.97% |
| 2021 FY | 4.84 Billion USD | 1290.97% |
| 2021 Q1 | -541.68 Million USD | -33.19% |
| 2021 Q2 | -658.16 Million USD | -21.5% |
| 2021 Q3 | 5.11 Billion USD | 876.44% |
| 2021 Q4 | 4.84 Billion USD | -5.22% |
| 2020 Q2 | -178.29 Million USD | -208.05% |
| 2020 Q1 | -57.87 Million USD | 11.98% |
| 2020 Q3 | -295.57 Million USD | -65.78% |
| 2020 Q4 | -406.69 Million USD | -37.59% |
| 2020 FY | -406.69 Million USD | -518.49% |
| 2019 Q4 | -65.75 Million USD | -679.45% |
| 2019 FY | -65.75 Million USD | -41.15% |
| 2019 Q3 | 11.34 Million USD | -80.7% |
| 2019 Q1 | 14.88 Million USD | 131.95% |
| 2019 Q2 | 58.81 Million USD | 295.14% |
| 2018 Q1 | 76.97 Million USD | 16.58% |
| 2018 FY | -46.58 Million USD | -170.56% |
| 2018 Q4 | -46.58 Million USD | 39.54% |
| 2018 Q3 | -77.05 Million USD | -228.73% |
| 2018 Q2 | 59.85 Million USD | -22.25% |
| 2017 Q1 | 111.3 Million USD | -28.64% |
| 2017 FY | 66.02 Million USD | -57.67% |
| 2017 Q4 | 66.02 Million USD | -52.49% |
| 2017 Q3 | 138.98 Million USD | 15.4% |
| 2017 Q2 | 120.44 Million USD | 8.21% |
| 2016 FY | 155.97 Million USD | -36.62% |
| 2016 Q1 | 186.94 Million USD | -24.04% |
| 2016 Q2 | 179.85 Million USD | -3.79% |
| 2016 Q3 | 182.1 Million USD | 1.25% |
| 2016 Q4 | 155.97 Million USD | -14.35% |
| 2015 Q3 | 114.75 Million USD | 341.74% |
| 2015 FY | 246.08 Million USD | 306.97% |
| 2015 Q2 | -47.46 Million USD | 36.91% |
| 2015 Q1 | -75.24 Million USD | 36.72% |
| 2015 Q4 | 246.08 Million USD | 114.45% |
| 2014 Q3 | -153.57 Million USD | -88.87% |
| 2014 FY | -118.9 Million USD | 34.86% |
| 2014 Q1 | -236.65 Million USD | -29.66% |
| 2014 Q4 | -118.9 Million USD | 22.58% |
| 2014 Q2 | -81.31 Million USD | 65.64% |
| 2013 Q2 | -98.26 Million USD | 28.47% |
| 2013 FY | -182.51 Million USD | -60.04% |
| 2013 Q4 | -182.51 Million USD | -16.66% |
| 2013 Q3 | -156.45 Million USD | -59.22% |
| 2013 Q1 | -137.37 Million USD | -20.46% |
| 2012 FY | -114.04 Million USD | 4.35% |
| 2012 Q1 | -108.84 Million USD | 8.72% |
| 2012 Q4 | -114.04 Million USD | 4.46% |
| 2012 Q3 | -119.37 Million USD | -25.76% |
| 2012 Q2 | -94.92 Million USD | 12.79% |
| 2011 Q1 | -191.81 Million USD | 24.99% |
| 2011 FY | -119.23 Million USD | 53.33% |
| 2011 Q4 | -119.23 Million USD | 5.95% |
| 2011 Q3 | -126.78 Million USD | 27.78% |
| 2011 Q2 | -175.56 Million USD | 8.47% |
| 2010 Q2 | -220.76 Million USD | -30.26% |
| 2010 Q4 | -255.7 Million USD | -10.56% |
| 2010 FY | -255.5 Million USD | -76.82% |
| 2010 Q1 | -169.48 Million USD | -17.05% |
| 2010 Q3 | -231.28 Million USD | -4.77% |
| 2009 Q2 | 11.03 Million USD | -61.65% |
| 2009 FY | -144.5 Million USD | -402.32% |
| 2009 Q1 | 28.78 Million USD | -39.78% |
| 2009 Q3 | -39.67 Million USD | -459.41% |
| 2009 Q4 | -144.8 Million USD | -264.97% |
| 2008 Q2 | 35.76 Million USD | -28.36% |
| 2008 Q3 | -12.33 Million USD | -134.49% |
| 2008 FY | 47.79 Million USD | 165.59% |
| 2008 Q1 | 49.92 Million USD | 177.41% |
| 2008 Q4 | 47.79 Million USD | 487.5% |
| 2007 FY | 17.99 Million USD | 131.1% |
| 2007 Q1 | -44.47 Million USD | 23.16% |
| 2007 Q4 | 17.99 Million USD | 1601.04% |
| 2007 Q3 | 1.05 Million USD | 101.7% |
| 2007 Q2 | -62.27 Million USD | -40.03% |
| 2006 Q1 | -62.34 Million USD | -17.05% |
| 2006 FY | -57.87 Million USD | -6.19% |
| 2006 Q3 | -50.69 Million USD | 19.64% |
| 2006 Q4 | -57.87 Million USD | -14.17% |
| 2006 Q2 | -63.08 Million USD | -1.19% |
| 2005 Q1 | -41.89 Million USD | -31.03% |
| 2005 FY | -54.5 Million USD | 1.76% |
| 2005 Q4 | -53.26 Million USD | 8.35% |
| 2005 Q3 | -58.11 Million USD | -3.98% |
| 2005 Q2 | -55.89 Million USD | -33.4% |
| 2004 Q3 | -42.49 Million USD | 23.41% |
| 2004 Q2 | -55.47 Million USD | 17.34% |
| 2004 Q1 | -67.11 Million USD | -52.44% |
| 2004 FY | -55.47 Million USD | -396.0% |
| 2004 Q4 | -31.97 Million USD | 24.75% |
| 2003 Q1 | -11.35 Million USD | 31.46% |
| 2003 Q3 | -51.36 Million USD | -359.27% |
| 2003 FY | -11.18 Million USD | 54.43% |
| 2003 Q4 | -44.02 Million USD | 14.29% |
| 2003 Q2 | -11.18 Million USD | 1.53% |
| 2002 FY | -24.54 Million USD | -7340.71% |
| 2002 Q4 | -16.57 Million USD | 23.95% |
| 2002 Q3 | -21.79 Million USD | 11.22% |
| 2002 Q2 | -24.54 Million USD | -9.33% |
| 2002 Q1 | -22.45 Million USD | 20.73% |
| 2001 Q1 | -9.37 Million USD | -18.93% |
| 2001 Q4 | -28.32 Million USD | -145.4% |
| 2001 FY | 339 Thousand USD | 101.43% |
| 2001 Q3 | -11.54 Million USD | -3504.42% |
| 2001 Q2 | 339 Thousand USD | 103.61% |
| 2000 Q1 | -15 Million USD | -8.71% |
| 2000 Q4 | -7.88 Million USD | -95.49% |
| 2000 Q3 | -4.03 Million USD | 83.04% |
| 2000 Q2 | -23.78 Million USD | -58.51% |
| 2000 FY | -23.78 Million USD | -183.1% |
| 1999 Q4 | -13.8 Million USD | 9.21% |
| 1999 FY | -8.4 Million USD | 0.0% |
| 1999 Q2 | -8.4 Million USD | 0.0% |
| 1999 Q3 | -15.2 Million USD | -80.95% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 9124.186% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 60299.491% |
| Aspira Women's Health Inc. | -331 Thousand USD | 1075695.77% |
| Biodesix, Inc. | 34.3 Million USD | -10277.538% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 61526.126% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 286537.622% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 286537.622% |
| Bionano Genomics, Inc. | 34.88 Million USD | -10106.473% |
| CareDx, Inc | -47.97 Million USD | 7520.84% |
| Check-Cap Ltd. | -24.75 Million USD | 14481.249% |
| Castle Biosciences, Inc. | -83.53 Million USD | 4362.157% |
| DarioHealth Corp. | -7.54 Million USD | 47267.753% |
| Exact Sciences Corporation | 1.94 Billion USD | -82.637% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 4411.971% |
| Guardant Health, Inc. | 220.22 Million USD | -1516.615% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | -620.769% |
| Illumina, Inc. | 1.21 Billion USD | -193.264% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 65633.704% |
| iSpecimen Inc. | -2.14 Million USD | 165890.515% |
| Standard BioTools Inc. | 46.5 Million USD | -7555.404% |
| MDxHealth SA | 18.88 Million USD | -18752.115% |
| 23andMe Holding Co. | -141.37 Million USD | 2618.336% |
| Medpace Holdings, Inc. | -103.32 Million USD | 3545.587% |
| Myriad Genetics, Inc. | 88.1 Million USD | -3941.115% |
| Mainz Biomed B.V. | 349.85 Thousand USD | -1017527.874% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 146040.404% |
| NeoGenomics, Inc. | 269.19 Million USD | -1222.564% |
| Neogen Corporation | 735.62 Million USD | -383.97% |
| Inotiv, Inc. | 382.14 Million USD | -831.632% |
| Natera, Inc. | -200.1 Million USD | 1879.204% |
| OpGen, Inc. | 11.89 Million USD | -29838.253% |
| OPKO Health, Inc. | 230.68 Million USD | -1443.34% |
| Psychemedics Corporation | 334 Thousand USD | -1065834.731% |
| Prenetics Global Limited | -43.33 Million USD | 8315.19% |
| Prenetics Global Limited | -43.33 Million USD | 8315.19% |
| Precipio, Inc. | -386 Thousand USD | 922437.306% |
| Personalis, Inc. | -8.02 Million USD | 44480.728% |
| RadNet, Inc. | 1.14 Billion USD | -209.975% |
| Sera Prognostics, Inc. | -2.02 Million USD | 176174.283% |
| Sotera Health Company | 2.02 Billion USD | -75.779% |
| Neuronetics, Inc. | 2.79 Million USD | -127187.165% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 23313.288% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 23313.288% |
| Trinity Biotech plc | 63.73 Million USD | -5485.889% |
| T2 Biosystems, Inc. | 33.8 Million USD | -10430.397% |
| Twist Bioscience Corporation | -192.4 Million USD | 1950.418% |
| Exagen Inc. | -12.77 Million USD | 27975.211% |